No Picture
Trading Ideas

Moderna Jumps as Analyst Sees Over $5 Billion Vaccine Sales

(Bloomberg) — Moderna Inc.’s experimental vaccine for Covid-19 could generate sales of more than $5 billion a year, Jefferies analyst Michael Yee said, initiating the stock at a buy.The shares jumped as much as 5.6% in Monday trading after the bullish review. A more than 230% surge for the stock since the start of the year has split Wall Street as to “what will happen or if the vaccine will even work,” and investors are “hugely divided on valuation,” Yee wrote in his note to clients.“We believe the Street will be surprised to the upside if the Covid-19 vaccine works, …read more […]

No Picture
Trading Ideas

3 Safe Dividend Stocks Yielding 5%; Piper Sandler Says ‘Buy’

‘Be safe’ has become a standard greeting these days, an expression of concern between friends during a time of pandemic disease and widespread civic disturbances. It’s also a piece of wise advice for investors. Mixed messages from the markets are confusing investors – some indexes, the Dow Jones particularly but to a lesser extent the S&P 500, are indicating that we’ve reached plateau in the bull rally, while the NASDAQ continues its upward tear.Dividend stocks have long been a traditional ‘safe zone’ for investors looking for some portfolio protection. While these stocks typically offer a lower-than-average share appreciation, the dividend …read more […]

No Picture
Trading Ideas

Stone Says He’ll Win on Appeal After Sentence Is Commuted

Jul.13 — President Donald Trump issued a commutation for the prison sentence of Roger Stone late Friday. Stone was convicted of witness tampering and lying to Congress during the Russian election interference investigation. Stone is a political operative and long-time ally of Trump. Stone spoke to reporters in Florida on Saturday. …read more […]

No Picture
Trading Ideas

Pfizer, BioNTech Score Fast Track Status For Covid-19 Vaccine Candidates

Pfizer Inc (PFE) and BioNTech SE (BNTX) have announced that two of the companies’ four investigational Covid-19 vaccine candidates from their BNT162 mRNA-based vaccine program have received Fast Track designation from the U.S. Food and Drug Administration (FDA).Shares in Pfizer are up 3% in Monday’s pre-market trading, while BioNTech has soared 9%.The two candidates, BNT162b1 and BNT162b2, are the most advanced vaccine candidates in the BNT162 program currently being evaluated in ongoing Phase 1/2 clinical studies in the United States and Germany.Fast Track is a process designed to facilitate the development, and expedite the review, of new drugs and vaccines …read more […]

No Picture
Trading Ideas

Pfizer, BioNTech's coronavirus vaccine candidates get FDA's 'fast track' status

The candidates, BNT162b1 and BNT162b2, are the most advanced of the at least four vaccines being assessed by the companies in ongoing trials in the United States and Germany. Pfizer’s shares were up about 2% and U.S.-listed shares of BioNTech were up about 6% before the bell. Earlier this month, the companies said BNT162b1 showed potential against the virus and was found to be well tolerated in early-stage human trials. …read more […]

No Picture
Trading Ideas

Disney World Cautiously Reopens; Analyst Optimistic On Outlook

Walt Disney Co. (DIS) reopened its popular theme park, Disney World on July 10 after closing nearly four months ago as a result of the COVID-19 outbreak.The theme park reported attendance for its two areas, Magic Kingdom and Animal Kingdom with a combined 16,000 visitors for the reopening. This falls well below the pre-COVID average of nearly 100,000 people per day. Disney plans to reopen the remainder of its park on July 15.Disney’s stock was up 2% at market close on July 10 at $119.32 per share.Disney is requiring everyone in the park to wear a mask except for swimming …read more […]

No Picture
Trading Ideas

Equillium Explodes 260% On Positive Covid-19 Results; India Approval

Shares in biotech Equillium (EQ) have almost tripled in Monday’s pre-market trading after the company announced that a clinical trial conducted in India by its partner Biocon demonstrated that itolizumab significantly reduced mortality in patients hospitalized with COVID-19.Equillium is currently developing itolizumab to treat severe autoimmune and inflammatory disorders. The stock is currently trading up 260% in the pre-market.Biocon also announced that the Drugs Controller General of India (DCGI) has granted restricted emergency use of itolizumab for the treatment of cytokine release syndrome (CRS) in COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) in India.Based on the …read more […]